Anebulo Pharmaceuticals, Inc. (ANEB)
$
0.66
+0.11 (16.67%)
Key metrics
Financial statements
Free cash flow per share
-0.1422
Market cap
27 Million
Price to sales ratio
0
Debt to equity
0
Current ratio
16.7136
Income quality
0.7320
Average inventory
0
ROE
-0.7458
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Anebulo Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing and commercializing treatments for individuals facing acute cannabinoid intoxication and substance addiction. The net income ratio is 0.00 reflecting the company's profitability margin. Additionally, the income before tax ratio is 0.00 showcasing the pre-tax margin. The company reported an income before tax of -$8,484,763.00 indicating its pre-tax profitability. Furthermore, the earnings per share (EPS) is reported at -$0.25 which highlights the company's profitability on a per-share basis. The EBITDA ratio is 0.00 underscoring the company's operational efficiency. Established in 2020 and headquartered in Lakeway, Texas, Anebulo is committed to advancing its lead product candidate, ANEB-001, a small molecule cannabinoid receptor antagonist aimed at treating cannabinoid intoxication and overdose. The stock is affordable at $2.52 making it suitable for budget-conscious investors. The stock has a low average trading volume of 117,231.00 indicating lower market activity. With a market capitalization of $26,950,550.00 the company is classified as a small-cap player. It is a key player in the Biotechnology industry, contributing significantly to the overall market landscape. Furthermore, it belongs to the Healthcare sector, driving innovation and growth. As Anebulo Pharmaceuticals navigates its clinical stages and prepares for market potential, its financial metrics, market positioning, and stock accessibility cater to a diverse range of investors who are interested in the biotechnology sector and its advancements.
Is Anebulo Pharmaceuticals, Inc. (ANEB) a good investment?
Investing in Anebulo Pharmaceuticals, Inc. (ANEB) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C-, with a Bullish outlook. Always conduct your own research before investing.
What is Anebulo Pharmaceuticals, Inc. (ANEB)'s stock forecast?
Analysts predict Anebulo Pharmaceuticals, Inc. stock to fluctuate between $0.30 (low) and $3.42 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Anebulo Pharmaceuticals, Inc.'s market capitalization?
As of 2026-03-16, Anebulo Pharmaceuticals, Inc.'s market cap is $26,950,550, based on 40,784,731 outstanding shares.
How does Anebulo Pharmaceuticals, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Anebulo Pharmaceuticals, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Anebulo Pharmaceuticals, Inc. (ANEB) stock?
To buy Anebulo Pharmaceuticals, Inc. (ANEB) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ANEB. Place an order (Market, Limit, etc.).
What is the best time to invest in Anebulo Pharmaceuticals, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
How did Anebulo Pharmaceuticals, Inc. perform in the last earnings report?
Revenue: $0 | EPS: -$0.25 | Growth: -21.88%.
Where can I find Anebulo Pharmaceuticals, Inc.'s investor relations reports?
Visit https://www.anebulo.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Anebulo Pharmaceuticals, Inc.?
You can explore historical data from here
What is the all-time high and low for Anebulo Pharmaceuticals, Inc. stock?
All-time high: $7.89 (2022-02-01) | All-time low: $0.30 (2026-03-03).
What are the key trends affecting Anebulo Pharmaceuticals, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
defenseworld.net
5 days ago
Replimune Group (NASDAQ: REPL - Get Free Report) and Anebulo Pharmaceuticals (NASDAQ: ANEB - Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, analyst recommendations, risk, earnings, profitability and institutional ownership. Risk and Volatility Replimune Group has a
businesswire.com
a month ago
AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the “Company” or “Anebulo”), today announced financial results for the three months ended December 31, 2025, and recent updates. Second Quarter Fiscal Year 2026 and Subsequent Highlights: On February 6, 2026, Anebulo announced that the Company's board of directors (the “Board”) approved th.
businesswire.com
a month ago
AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the “Company” or “Anebulo”), today announced that the Company's board of directors (the “Board”) has approved the voluntary delisting of the Company's common stock from The Nasdaq Capital Market (“Nasdaq”) and the subsequent voluntary deregistration of its common stock with the U.S. Securi.
defenseworld.net
a month ago
Anebulo Pharmaceuticals, Inc. (NASDAQ: ANEB - Get Free Report)'s stock price dropped 13.6% on Thursday. The stock traded as low as $0.8031 and last traded at $0.8212. Approximately 42,620 shares were traded during trading, a decline of 31% from the average daily volume of 62,014 shares. The stock had previously closed at $0.9501. Anebulo Pharmaceuticals
defenseworld.net
a month ago
Anebulo Pharmaceuticals, Inc. (NASDAQ: ANEB - Get Free Report)'s share price was down 13.6% during trading on Thursday. The company traded as low as $0.8031 and last traded at $0.8212. Approximately 42,620 shares were traded during mid-day trading, a decline of 31% from the average daily volume of 62,014 shares. The stock had previously closed
businesswire.com
2 months ago
AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the “Company” or “Anebulo”), today announced the final results of its voluntary self-tender offer to purchase 300,000 shares of its common stock, par value $0.001 per share (“Common Stock”), which expired one minute after 11:59 p.m., New York City time, on January 26, 2026. Based on the fi.
businesswire.com
2 months ago
AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals Announces Preliminary Results of Tender Offer.
businesswire.com
3 months ago
AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the “Company” or “Anebulo”), today announced that the Board of Directors has decided to commence a cash tender offer as part of its plan to “go private” in lieu of the previously announced reverse stock split at a ratio of not less than 1-for-2,500 and not greater than 1-for-7,500. Volunta.
businesswire.com
4 months ago
AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2026 Financial Results and Recent Updates.
businesswire.com
6 months ago
AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Recent Updates.
See all news
